All In Biotech

Drug Trial Radar · NCT05604170

Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy

A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

117

Actual

Start

May 16, 2022

Primary completion

Apr 2, 2025

Study completion Apr 2, 2025

Sponsor

Lead sponsor
Marinus PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Nov 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, global, open-label extension (OLE) study of adjunctive GNX treatment in children and adults with TSC who previously participated in either Study 1042-TSC-3001 or Study 1042-TSC-2001

Conditions

  • Tuberous Sclerosis Complex

Interventions

  • GanaxoloneDrug

    GNX will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Withdrawals and Dose-Reductions Due to AEsTime frame: Up to 150 Weeks
  2. Number of Participants With Clinically Significant Changes in Vital ParametersTime frame: Up to 150 Weeks
  3. Number of Participants With Clinically Significant Changes in Physical ExaminationsTime frame: Up to 150 Weeks
  4. Number of Participants With Clinically Significant Changes in Neurological ExaminationsTime frame: Up to 150 Weeks
  5. Number of Participants With Clinically Significant Changes in Developmental ExaminationsTime frame: Up to 150 Weeks
  6. Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) FindingsTime frame: Up to 150 Weeks
  7. Number of Participants With Clinically Significant Changes in Hematology ParametersTime frame: Week 1 through Week 150
  8. Number of Participants With Clinically Significant Changes in Chemistry ParametersTime frame: Up to 150 Weeks
  9. Number of Participants With Clinically Significant Changes in UrinalysisTime frame: Up to 150 Weeks
  10. Number of Participants (Age Greater Than 17 Years) With Abnormal Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: Up to Week 52

Locations

54 sites in 10 countries. Site status is shown where the registry gives one.

  • Arkansas Children's Research Institute

    Little Rock, Arkansas

  • UCLA Mattel Children's Hospital, TSC Center

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • Rady Children's Hospital - San Diego

    San Diego, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Nemours Children's Hospital - Delaware Valley

    Wilmington, Delaware

  • Boston Children's Hospital, Harvard Medical School

    Boston, Massachusetts

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Children's Mercy Hospital

    Kansas City, Missouri

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Atrium Health/Levine Children's Hospital

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Le Bonheur Children's Hospital

    Memphis, Tennessee

  • Child Neurology Consultants of Austin (CNCA)

    Austin, Texas

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • McGovern Medical School at the University of Texas Health Science Center

    Houston, Texas

  • University of Utah Health Care-Pediatric Neurology

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • Austin Health

    Heidelberg, Australia

  • Royal Brisbane and Women's Hospital

    Herston, Australia

  • Alfred Health

    Melbourne, Australia

  • Royal Melbourne Hospital

    Parkville, Australia

  • Hôtel Dieu de Montréal - CHUM

    Montreal, Canada

  • CHU Sainte-Justine

    Montreal, Canada

  • The Hospital for Sick Children

    Toronto, Canada

  • Toronto Western Hospital

    Toronto, Canada

  • BC Children's Hospital

    Vancouver, Canada

  • Peking University First Hospital

    Beijing, China

  • Beijing Children Hospital, Capital Medical University

    Beijing, China

  • Chinese PLA General Hospital

    Beijing, China

  • The Affiliated Hospital of Guizhou Medical University

    Beijing, China

  • First Hospital of Jilin University

    Jilin City, China

  • University Hospital of Lyon

    Bron, France

  • Hôpital Sud

    Rennes, France

  • University of Strasbourg

    Strasbourg, France

  • Epilepsie-Zentrum Bethel - Krankenhaus Mara

    Bielefeld, Germany

  • University Hospital Bonn

    Bonn, Germany

  • ZNN - Epilepsiezentrum Frankfurt am Main

    Frankfurt, Germany

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.